Emergent BioSolutions said Johnson & Johnson has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter’s COVID-19 vaccine.
Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly’s own treatment Mounjaro leads to faster and greater weight loss.
In its lawsuit filed in August 2023, the pharma argued that the negotiation program is voluntary only in name. By leveraging Medicare and Medicaid—which account for around half of the market—the government is essentially forcing the companies to participate in the drug price negotiations.
While HIL-214 was being tested in infants, children and adults, HilleVax said it will discontinue the vaccine’s development for infants.
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.
Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.